Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

PURPOSE: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and advanced metastatic MCC frequently responds to PD...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Topalian, Suzanne L., Bhatia, Shailender, Amin, Asim, Kudchadkar, Ragini R., Sharfman, William H., Lebbé, Celeste, Delord, Jean-Pierre, Dunn, Lara A., Shinohara, Michi M., Kulikauskas, Rima, Chung, Christine H., Martens, Uwe M., Ferris, Robert L., Stein, Julie E., Engle, Elizabeth L., Devriese, Lot A., Lao, Christopher D., Gu, Junchen, Li, Bin, Chen, Tian, Barrows, Adam, Horvath, Andrea, Taube, Janis M., Nghiem, Paul
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2020
Sujets:
Rapid Communications
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7392746/
https://ncbi.nlm.nih.gov/pubmed/32324435
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00201
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires